Business Wire

Synteract Announces Collaboration with International Children’s Advisory Network iCAN Research

Del

Synteract, an innovative contract research organization (CRO) providing full, phase I-IV services enabling drug development companies to bring new medicines to market, has signed a memo of understanding to partner with the International Children’s Advisory Network (iCAN). A worldwide consortium of children’s advisory groups, iCAN is dedicated to giving children and families a voice in health, medicine, research, and innovation by increasing education about the importance of children’s involvement. Synteract is a sponsor at the 2018 iCAN Research Summit in Edinburgh, Scotland, UK, July 8-13, 2018 and will hold two interactive plenary seminar sessions at the event.

With chapters across the U.S. and worldwide, iCAN partners with local children’s hospitals and addresses the needs of pediatric clinical research and healthcare and advocates for patients worldwide.

In partnering with iCAN, Synteract will expand its access to children and families familiar with clinical research. iCAN will support Synteract by sharing ideas, best practices in study designs, protocol review intended for pediatric treatment, and patient facing documents review to help increase recruitment and enhance the quality and benefit of pediatric clinical trials and pediatric research. Both organizations will capitalize on opportunities for innovation in leveraging their respective expertise to enable children and their families to take ownership of their health, provide meaningful input into regulations, and improve design and conduct of pediatric studies worldwide.

“At iCAN, we are dedicated to advancing the health and well-being of children around the world. An important part of that is collaborating with established partners, such as Synteract in the pediatric clinical trials space,” said Leanne West, president of iCAN. “We look forward to working together to leverage Synteract’s extensive knowledge, industry experience, and drug development acumen to further advance pediatric clinical research and increase availability of medicines to help children.”

Synteract has been at the forefront of working with sponsors in pediatric clinical trials for three decades, with 100 pediatric studies performed worldwide across multiple therapeutic indications. It recently announced pediatrics drug development as one of its focused therapeutic centers of development.

Dr. Martine Dehlinger-Kremer heads up the pediatric center of development at Synteract, as vice president, Pediatric Development. She is also President of EUCROF, the European CRO Federation; Chair of the Pediatric Working Group of EUCROF since 2008, and Chair of the European Forum for GCP Children Medicines Working Party. She was appointed Observer Member of the Coordinating Group of Enpr-EMA, the European Network of Pediatric Research at the European Medicines Agency (EMA), in April 2018, and has been a member of Working Parties of Enpr-EMA for several years.

“At Synteract we remain committed to advancing standards and assisting sponsors to address growing needs for pediatric clinical research,” said Dr. Dehlinger-Kremer. “By partnering with iCAN, we gain access to its wide network of children and families spanning socioeconomic, cultural, and geographic backgrounds, which will be beneficial for the development of medicines for children. Our partnership with iCAN will be valuable in developing better, more appropriate protocols, study designs, patient facing documents and setting strategy for recruitment. It will also help us to further innovation in systems and treatments. It is another important step to show our commitment to this important population.”

iCAN is supported by the Foundation for Children, the 501 (c) 3 nonprofit arm of the Connecticut Chapter of the American Academy of Pediatrics (CT-AAP).

About Synteract

With 800 staff members across 21 countries, Synteract is an innovative, full-service contract research organization supporting biopharmaceutical companies in all phases of clinical development to help bring new medicines to market. Synteract has conducted nearly 4,000 studies on six continents and in more than 60 countries, working with more than 26,000 investigative sites and nearly 750,000 patients. It has contributed to more than 240 product approvals. The CRO offers a notable depth of expertise in pediatric, oncology and neuro degenerative indications, as well as rare and orphan and immunotherapy studies.

Contact information

for Synteract
Hilary McCarthy, 508-829-2543
hilary@clearpointagency.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

MapleStory Prepares for Epic Battle Against the Black Mage in Gathering of Heroes Event14.11.2018 21:00Pressemelding

MapleStory, the iconic global MMORPG from Nexon America, is bringing the first phase of its long-awaited battle with the sinister villain, the Black Mage. Between November 14 through November 28, players can take part in the “Gathering of Heroes” event to join the Maple Alliance and prepare their armies to soon combat the Black Mage. The Black Mage has long been the main antagonist behind MapleStory. His story originated with the role of bringing balance to Maple World, but turned dark as he realized the only way to save Maple World was to destroy it. Now that his seal has been broken, players will need to work together to defeat the legendary boss. The Gathering of Heroes event adds the Maple Alliance outpost, where players can hone their skills and prepare to level up in preparation of for their battle against the Black Mage, as well as adds various leveling updates. The main goal of the Alliance is to gather “Determination” and power up the holy light in the outpost to be able to fi

SpinalCyte Announces Sustained 12-Month MRI Outcomes After CybroCell™ Injection14.11.2018 20:07Pressemelding

SpinalCyte, LLC, a Texas-based regenerative medicine company focused on regrowth of the spinal disc nucleus using its universal donor product, CybroCell™, today announced that a single injection of modified human dermal fibroblasts (HDFs), resulted in significant improvements of disc height and pain reduction 12 months after injection of the cell therapy for patients with degenerative disc disease (DDD). The trial assessed patients using the Oswestry Disability Index (ODI), Visual Analogue Scale (VAS) and disc height via MRI scans. Using composite scoring, 54% of the treatment arm patients met all three endpoints as compared to only 17% with the placebo (p=0.0003). Over 84% of patients in the treatment group of CybroCell™ or CybroCell™ with platelet rich plasma (PRP) injections had an increase or no change in disc height compared to 25% for the placebo saline injection. Analyzed individually, 83% of spinal discs that were injected with CybroCell™ had an increase or no change in disc he

Raising Awareness about Early Onset Dementia: “Don’t Leave me now”, Written by Brian Daniels14.11.2018 16:55Pressemelding

The Fondation IPSEN is delighted to invite you to a theatre performance about familial upheavals when a family member is affected by Alzheimer’s disease or cerebral dementia (November 21 st at 4pm). This play has been written by playwright Brian Daniels and directed by Jeni Draper, has had more than 200 performances and explores with insight and humour the impact of early onset dementia on family life. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181114005695/en/ (Graphic: Business Wire) Free entrance, but registration is mandatory (limited seats): Please click here NOVEMBER 21 st , 4 pm “Le Petit Théâtre de la Fondation IPSEN” 65 quai George Gorse 92150 Boulogne-Billancourt (Metro Line 9, Pont-de-Sèvres) About the Project Our “Science for People” program is composed of accessible meetings and webinars to improve access to science. Brian Daniels’ play “Don’t leave me now” is about caregivers of people with Alzheimer’s Dise

HCL Technologies Celebrates 10 Years of Success in the Nordics14.11.2018 16:44Pressemelding

HCL Technologies (HCL), a leading global technology company, is celebrating its 10-year anniversary in the Nordic region. During this time, the company has achieved significant successes, which have seen the Nordics grow to become HCL’s largest market in Europe. Today, HCL employs more than 1,600 people in the Nordics representing 31 nationalities, with 55 large-scale transformational clients including four out of the six Fortune Global 500 companies in the region. While several significant milestones have been successfully achieved, HCL looks forward to the future and is dedicated to helping its clients in the Nordics to drive innovation and growth. The celebration coincides with a series of initiatives to mark this occasion starting with the opening of a new office at HCL’s Nordics headquarters in Central Stockholm. “We are humbled by the success that we have achieved together with our clients, colleagues and partners in the Nordics,” said Pankaj Tagra, EVP Nordic and DACH Head, HCL

The Next Industrial Transformation is Here: Rockwell Automation is Helping Businesses Prepare to Succeed at Automation Fair 201814.11.2018 16:35Pressemelding

Today, at its annual Automation Fair, Rockwell Automation unveiled its new brand promise: Expanding Human Possibility by combining the imaginations of people with the intelligence of machines. The brand promise supports the company’s emphasis on bringing The Connected Enterprise to life and how, by linking people, machines and data across an entire business, manufacturers become more effective and productive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181114005671/en/ Blake Moret, chairman and CEO, Rockwell Automation, shares his vision for bringing the Connected Enterprise to life and how manufacturers can expand human possibility by linking people, machines and data across their businesses, helping them to become more effective and productive. (Photo: Business Wire) “The new Rockwell Automation brand emphasizes the central role that people play in advanced manufacturing and underscores our focus on ways we maximize per

Hospital in Cox’s Bazar Will Offer 24/7 Medical Aid to 140,000 Rohingya Refugees14.11.2018 15:53Pressemelding

A 100-bed capacity hospital opened in Cox’s Bazar district in Bangladesh. It is expected to serve 140,000 Rohingya refugees based in the Kutupalong camp. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181114005631/en/ Sheikh Sultan bin Ahmed Al Qasimi, humanitarian envoy of the foundation and chairman of SMC inaugurated the hospital last Friday. (Photo: Business Wire) This round-the-clock medical facility, built and managed by Médecins Sans Frontières (MSF) – Doctors without Borders with the support of Sharjah-based international humanitarian organisation, The Big Heart Foundation (TBHF), aims to treat 7,200 people in its first year. Part of TBHF’s leading humanitarian efforts to reach out globally to vulnerable communities, this hospital project was supported by AED 3 million donation from Sharjah Media Corporation (SMC), through its public fundraising initiative on healthcare projects, and will offer much-needed relief to